%0 Journal Article
%T Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System
%A A. Jon Stoessl
%A Alessandro Tessitore
%A Alexander Drzezga
%A Angelo Antonini
%A Antonio P. Strafella
%A Axel Rominger
%A Daniela Berg
%A Gregor Wenning
%A G¨¹nter U. H£¿glinger
%A Hartwig R. Siebner
%A Irena Rektorov¨¢
%A James B. Rowe
%A Jos¨¦ ¨¢ngel Pineda-Pardo
%A Klaus Seppi
%A Makoto Higuchi
%A Mar¨ªa Cecilia Peralta
%A Mar¨ªa Rodr¨ªguez-Oroz
%A Matej Ondrus
%A Nico Bohnen
%A Nicola Pavese
%A Oury Monchi
%A Paola Piccini
%A Peter Nestor
%A Roberto Ceravolo
%A Simon Lewis
%A Stephane Lehericy
%A Stephane Thobois
%A Valtteri Kaasinen
%J Archive of "Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring".
%D 2019
%R 10.1016/j.dadm.2019.01.011
%X Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders
%K Biomarker
%K Trials
%K PSP
%K MSA
%K CBD
%K CBS
%K Neurodegeneration
%K Biomarker
%K Multicentric
%K Multisite
%K Neuroimaging
%K Harmonization
%K PET
%K MRI
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446052/